{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T10:49:26Z","timestamp":1769597366511,"version":"3.49.0"},"reference-count":71,"publisher":"Impact Journals, LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2017,2,7]]},"DOI":"10.18632\/oncotarget.13314","type":"journal-article","created":{"date-parts":[[2016,11,12]],"date-time":"2016-11-12T03:20:55Z","timestamp":1478920855000},"page":"10748-10759","source":"Crossref","is-referenced-by-count":15,"title":["Magic year for multiple myeloma therapeutics: Key takeaways from the ASH 2015 annual meeting"],"prefix":"10.18632","volume":"8","author":[{"given":"Kejie","family":"Zhang","sequence":"first","affiliation":[{"name":"Department of Hematology, Zhongshan Hospital, Xiamen University, Fujian Medical University Clinic Teaching Hospital, Xiamen, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aakash","family":"Desai","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"},{"name":"University of Texas Health Science Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongfeng","family":"Zeng","sequence":"additional","affiliation":[{"name":"Department of Hematology, Xinqiao hospital, Third Military Medical University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tiejun","family":"Gong","sequence":"additional","affiliation":[{"name":"Institute of Hematology and Oncology, Harbin first Hospital, Harbin, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peihua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Hematology, Hebei Yanda Ludaopei Hospital, Beijing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma\/Myeloma, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"7892","published-online":{"date-parts":[[2016,11,11]]},"reference":[{"issue":"1","key":"1","first-page":"11","article-title":"Cancer statistics, 2013","volume":"63","author":"Jemal","year":"2013","journal-title":"CA: a cancer journal for clinicians"},{"issue":"4","key":"2","doi-asserted-by":"crossref","first-page":"389","DOI":"10.6004\/jnccn.2016.0046","article-title":"NCCN Guidelines Insights: Multiple Myeloma, Version 3.2016","volume":"14","author":"Godby","year":"2016","journal-title":"Journal of the National Comprehensive Cancer Network"},{"issue":"1","key":"3","first-page":"1","article-title":"Access to new cancer medicines in Australia: dispelling the myths and informing a public debate","volume":"9","author":"Lipworth","year":"2016","journal-title":"Journal of pharmaceutical policy and practice"},{"issue":"3","key":"4","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1517\/14728214.2012.713345","article-title":"Emerging biological insights and novel treatment strategies in multiple myeloma","volume":"17","author":"Morabito","year":"2012","journal-title":"Expert opinion on emerging drugs"},{"key":"5","doi-asserted-by":"crossref","first-page":"e338","DOI":"10.1038\/bcj.2015.60","article-title":"Phase 2 trial of ixazomib in patients with relapsed multiple myeloma not refractory to bortezomib","volume":"5","author":"Fonseca","year":"2015","journal-title":"Blood Cancer J"},{"issue":"4","key":"6","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1042\/BST20140126","article-title":"Overcoming bortezomib resistance in multiple myeloma","volume":"42","author":"Bowles","year":"2014","journal-title":"Biochem Soc Trans"},{"issue":"4","key":"7","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1177\/1078155212470388","article-title":"Carfilzomib: A new proteasome inhibitor for relapsed or refractory multiple myeloma","volume":"19","author":"Steele","year":"2013","journal-title":"J Oncol Pharm Pract"},{"issue":"22","key":"8","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.2174\/1381612811319220012","article-title":"From bortezomib to other inhibitors of the proteasome and beyond","volume":"19","author":"Dou","year":"2013","journal-title":"Curr Pharm Des"},{"key":"9","doi-asserted-by":"crossref","first-page":"217","DOI":"10.2147\/DDDT.S93602","article-title":"Spotlight on ixazomib: potential in the treatment of multiple myeloma","volume":"10","author":"Azab","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"10","first-page":"126","article-title":"Ixazomib, an Investigational Oral Proteasome Inhibitor (PI), in Combination with Lenalidomide and Dexamethasone (IRd), Significantly Extends Progression-Free Survival (PFS) for Patients (Pts) with Relapsed and\/or Refractory Multiple Myeloma (RRMM The Phase 3 Tourmaline-MM1 Study (NCT01564537)","volume":"727","author":"Gimsing","year":"2015","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/S1470-2045(14)71125-8","article-title":"Safety and tolerability of ixazomib, an oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma: an open-label phase 1\/2 study","volume":"15","author":"Liao","year":"2014","journal-title":"The Lancet Oncology"},{"key":"12","first-page":"126","article-title":"Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT0070)","volume":"26","author":"Grzasko","year":"2015","journal-title":"Blood"},{"issue":"7","key":"13","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Lonial","year":"2014","journal-title":"Blood"},{"key":"14","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1517\/14656566.2013.805746","article-title":"New developments in the management and treatment of newly diagnosed and relapsed\/refractory multiple myeloma patients","volume":"14","author":"de Donk","year":"2013","journal-title":"Expert opinion on pharmacotherapy"},{"key":"15","first-page":"149","article-title":"International Myeloma Working Group. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib a multicenter international myeloma working group study","author":"Klein","year":"2012","journal-title":"Leukemia"},{"issue":"6","key":"16","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1182\/blood-2015-10-646810","article-title":"Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma","volume":"127","author":"Richardson","year":"2016","journal-title":"Blood"},{"key":"17","doi-asserted-by":"crossref","first-page":"199","DOI":"10.14694\/EdBook_AM.2014.34.199","article-title":"Where we were, where we are, where we are going: progress in multiple myeloma","author":"Bergsagel","year":"2014","journal-title":"American Society of Clinical Oncology educational book \/ ASCO American Society of Clinical Oncology Meeting"},{"key":"18","first-page":"42","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","author":"Anderson","year":"2015","journal-title":"Nature reviews Clinical oncology"},{"issue":"2","key":"19","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/leu.2011.214","article-title":"Monoclonal antibody-based therapy as a new treatment strategy in multiple myeloma","volume":"26","author":"Lokhorst","year":"2012","journal-title":"Leukemia"},{"key":"20","first-page":"1264","article-title":"Monoclonal Antibodies in Multiple Myeloma Come of Age","author":"Longo","year":"2015","journal-title":"N. and J"},{"key":"21","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/leu.2015.223","article-title":"Monoclonal antibodies in the treatment of multiple myeloma: current status and future perspectives","volume":"30","author":"San-Miguel","year":"2016","journal-title":"Leukemia"},{"issue":"1","key":"22","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/imr.12389","article-title":"Monoclonal antibodies targeting CD38 in hematological malignancies and beyond","volume":"270","author":"Parren","year":"2016","journal-title":"Immunol Rev"},{"key":"23","doi-asserted-by":"crossref","unstructured":"Weers, Tai, Veer, Bakker, Vink, Jacobs, Oomen, Peipp, Valerius, Slootstra, Mutis, Bleeker, Anderson, De Van Der. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. 2011. 186 SRC - GoogleScholar; 1840\u20131848.","DOI":"10.4049\/jimmunol.1003032"},{"key":"24","first-page":"311","article-title":"Lammerts Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma","author":"B\u00a8ogels","year":"2015","journal-title":"MAbs"},{"issue":"10","key":"25","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1038\/bcj.2011.42","article-title":"The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies","volume":"1","author":"Mutis","year":"2011","journal-title":"Blood Cancer J"},{"key":"26","article-title":"Daratumumab, a human CD38 antibody induces apoptosis of myeloma tumor cells via fc receptor-mediated crosslinking","volume":"120","author":"Marco","year":"2012","journal-title":"Blood 2974"},{"key":"27","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS an open-label, randomised, phase 2 trial","volume":"387","author":"Sutherland","year":"2016","journal-title":"Lancet"},{"key":"28","unstructured":"Horsham. 2016. Darzalex package insert."},{"key":"29","article-title":"Daratumumab in Combination with Lenalidomide and Dexamethasone in Patients with Relapsed or Relapsed and Refractory Multiple Myeloma: Updated Results of a Phase 1\/2 Study (GEN503)","volume":"507","author":"Sasser","year":"2015","journal-title":"Blood"},{"key":"30","first-page":"126","article-title":"Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma","volume":"29","author":"Wang","year":"2015","journal-title":"Blood"},{"key":"31","first-page":"126","article-title":"Open-Label, Multicenter, Phase 1b Study of Daratumumab in Combination with Pomalidomide and Dexamethasone in Patients with at Least 2 Lines of Prior Therapy and Relapsed or Relapsed and Refractory Multiple Myeloma","author":"Krishnan","year":"2015","journal-title":"Blood 508"},{"key":"32","unstructured":"His, Steinle, Balasa, Szmania, Draksharapu, Shum, Huseni, Powers, Nanisetti, Zhang, Rice, van Abbema, Wong. 2008. CS1, a potential new therapeutic antibody target for the treatment of multiple myeloma."},{"issue":"7","key":"33","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","volume":"373","author":"Orlowski","year":"2015","journal-title":"The New England journal of medicine"},{"key":"34","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s00262-013-1493-8","article-title":"Elotuzumab directly enhances NK cell cytotoxicity against myeloma via CS1 ligation: evidence for augmented NK cell function complementing ADCC","volume":"62","author":"Rice","year":"2013","journal-title":"Cancer Immunol Immunother"},{"key":"35","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1128\/MCB.01107-14","article-title":"Immune cell inhibition by SLAMF7 is mediated by a mechanism requiring src kinases, CD45, and SHIP-1 that is defective in multiple myeloma cells","volume":"35","author":"Veillette","year":"2015","journal-title":"Mol Cell Biol"},{"key":"36","first-page":"727","article-title":"P\u00e9rez- EAT-2, a SAP-like adaptor, controls NKcell activation through phospholipase C\u03b3, Ca++, and Erk, leading to granule polarization","author":"Veillette","year":"2014","journal-title":"Med"},{"key":"37","first-page":"1329","article-title":"Anti-CS1 humanized monoclonal antibody HuLuc63 inhibits myeloma cell adhesion and induces antibody-dependent cellular cytotoxicity in the bone marrow milieu","author":"Caras","year":"2008","journal-title":"Blood"},{"issue":"1","key":"38","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple Myeloma: Diagnosis and Treatment","volume":"91","author":"Kumar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"8 Spec Issue","key":"39","first-page":"17","article-title":"Elotuzumab, first-in-class monoclonal antibody immunotherapy, improves outcomes in patients with multiple myeloma","author":"Starr","year":"2015","journal-title":"American health & drug benefits"},{"key":"40","first-page":"126","article-title":"Eloquent-2 Update: 3, of Elotuzumab in Combination with Lenalidomide\/Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma-3-Year Safety and Efficacy Follow-up","volume":"28","author":"MoreauP","year":"2015","journal-title":"Blood"},{"key":"41","first-page":"126","article-title":"De La Elotuzumab Plus Bortezomib and Dexamethasone Versus Bortezomib and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma: 2-Year Follow-up","author":"P\u00e9gourie","year":"2015","journal-title":"Blood 510"},{"key":"42","first-page":"621","article-title":"ELOQUENT-2 Investigators. Elotuzumab Therapy for Relapsed or Refractory Multiple Myeloma","author":"Beksac","year":"2015","journal-title":"J. and N"},{"key":"43","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","article-title":"PD-1 and its ligands in tolerance and immunity","volume":"26","author":"Sharpe","year":"2008","journal-title":"Annu Rev Immunol"},{"key":"44","doi-asserted-by":"crossref","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","article-title":"Induced expression of PD-1, a novelmember of the immunoglobulin gene superfamily, upon programmed cell death","volume":"11","author":"Honjo","year":"1992","journal-title":"EMBO J"},{"key":"45","article-title":"Co-inhibitory role of T-cell-associated and B7-DC in the T-cell immune response","author":"Choi","year":"2006","journal-title":"Immunol Lett 222228"},{"key":"46","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","article-title":"1-PD-L pathway in immunological tolerance","volume":"27","author":"Honjo","year":"2006","journal-title":"Trends Immunol"},{"key":"47","first-page":"1537","article-title":"Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired","author":"Rosenberg","year":"2009","journal-title":"Blood"},{"key":"48","first-page":"12293","article-title":"Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade","author":"Sci","year":"2002","journal-title":"Proc Natl Acad"},{"key":"49","first-page":"3167","article-title":"study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates","author":"Phase","year":"2010","journal-title":"Oncol"},{"key":"50","first-page":"3015","article-title":"PD-L1 regulates the development, maintenance, and function of induced regulatory T cells","author":"Sharpe","year":"2009","journal-title":"Med"},{"key":"51","doi-asserted-by":"crossref","first-page":"5393","DOI":"10.1158\/0008-5472.CAN-11-0993","article-title":"Pr\u00e9vost- IL-18 induces PD-1-dependent immunosuppression in cancer","volume":"71","author":"Schultze","year":"2011","journal-title":"Cancer Res"},{"key":"52","first-page":"431","volume-title":"Oncology","volume":"29","author":"Gordon","year":"2015"},{"key":"53","article-title":"Preliminary results of a phase I study of nivolumab(BMS-936558) in patients with relapsed or refractory lymphoid malignancies","author":"Chapuy","year":"2014","journal-title":"Blood 289"},{"key":"54","article-title":"San Pembrolizumab in Combination with Lenalidomide and Low-Dose Dexamethasone for Relapsed\/Refractory Multiple Myeloma (RRMM Keynote-023)","volume":"505","author":"Siegel","year":"2015","journal-title":"Blood"},{"key":"55","article-title":"I. A. of 1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in Patients with Relapsed\/Refractory Multiple Myeloma (RRMM)","volume":"506","author":"Singh","year":"2015","journal-title":"Blood"},{"issue":"1","key":"56","article-title":"The Role of Immunotherapy in Multiple Myeloma","volume":"9","author":"Badros","year":"2016","journal-title":"Pharmaceuticals (Basel)"},{"issue":"19","key":"57","first-page":"2048","article-title":"B-cell Maturation Antigen Is a Promising Target for cell Therapy of Multiple Myeloma","author":"Adoptive","year":"2013","journal-title":"Clinical cancer research"},{"key":"58","doi-asserted-by":"crossref","first-page":"3989","DOI":"10.1158\/1078-0432.CCR-13-2510","article-title":"Genetic modification of T cells redirected toward CS1 enhances eradication of myeloma cells","volume":"20","author":"Yu","year":"2014","journal-title":"Clinical cancer research"},{"issue":"1","key":"59","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/imr.12243","article-title":"Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies","volume":"263","author":"June","year":"2015","journal-title":"Immunol Rev"},{"key":"60","first-page":"126","article-title":"T. Remissions of Multiple Myeloma during a First-in-Humans Clinical Trial of Expressing an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor","author":"Kochenderfer","year":"2015","journal-title":"BloodLBA1"},{"issue":"3","key":"61","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/leu.2013.350","article-title":"New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG)","volume":"28","author":"Turesson","year":"2014","journal-title":"Leukemia"},{"key":"62","article-title":"The novel KSP inhibitor ARRY-520 is active both with and without low-dosedexamethasone in patients with multiple myeloma refractory to bortezomib andlenalidomide: results from a phase 2 study","volume":"120","author":"AS.","year":"2012","journal-title":"Meet Abstr 449"},{"key":"63","article-title":"A phase I study of ARRY-520 (filanesib) with bortezomib in relapsed or refractory multiple myeloma","author":"AS.","year":"1938","journal-title":"Meeting Poster"},{"key":"64","first-page":"126","article-title":"Phase 1 Study of the Novel Kinesin Spindle Protein Inhibitor Filanesib + Carfilzomib in Patients with Relapsed and\/or Refractory Multiple Myeloma (RRMM)","volume":"376","author":"AS.","year":"2015","journal-title":"Meeting. Abstr376.or Blood"},{"key":"65","article-title":"Phase 2 Study of Carfilzomib (CFZ) with or without Filanesib (FIL) in Patients with Advanced Multiple Myeloma (MM)","volume":"728","author":"AS.","year":"2015","journal-title":"Meeting. Abstr 728. or Blood"},{"key":"66","first-page":"25","article-title":"Expression, function, and targeting of the nuclear exporter chromosomeregion maintenance 1 (CRM1) protein","author":"Hail","year":"2015","journal-title":"Pharmacology & Therapeutics"},{"key":"67","article-title":"deNully Antitumor activity of selinexor (KPT-330), a first-inclass oral selective inhibitor of nuclear export (SINE) XPO1\/CRM1 antagonist in patients with relapsed\/refractory multiple myeloma (MM) or Waldenstrom\u2019smacroglobulinemia (WM). Meeting;","author":"AS.","year":"1942","journal-title":"Abstr"},{"issue":"2","key":"68","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1177\/1078155215572036","article-title":"Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease","volume":"22","author":"Redic","year":"2016","journal-title":"J Oncol Pharm Pract"},{"key":"69","unstructured":"NL. University of Chicago. Selinexor carfilzomib and dexamethasone in treating patients with relapsed or refractory multiple myeloma SINE ClinicalTrialsgov Internet National Library of Medicine US httpsclinicaltrialsgovct2showNCT0265 0265. 1996."},{"key":"70","doi-asserted-by":"crossref","unstructured":"Jakubowiak, Jasielec, Rosenbaum, Zonder, Cole, Chari, Nam, Stephens, Rosebeck, Rashal, McDonnell, Uribe, Youssoufian. Blood; 4223. 2015. 126 SRC - GoogleScholar.","DOI":"10.1182\/blood.V126.23.4223.4223"},{"key":"71","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1182\/blood-2015-03-575365","article-title":"Promising therapies in multiple myeloma","volume":"126","author":"Anderson","year":"2015","journal-title":"Blood"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13314","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,10]],"date-time":"2020-05-10T16:01:01Z","timestamp":1589126461000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.13314"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,11]]},"references-count":71,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,2,7]]}},"alternative-id":["13314","27863374"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.13314","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,11]]}}}